GLENMARK - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 4.0
| Stock Code | GLENMARK | Market Cap | 68,635 Cr. | Current Price | 2,431 ₹ | High / Low | 2,474 ₹ |
| Stock P/E | 46.3 | Book Value | 848 ₹ | Dividend Yield | 0.10 % | ROCE | 9.72 % |
| ROE | 7.35 % | Face Value | 1.00 ₹ | DMA 50 | 2,198 ₹ | DMA 200 | 1,996 ₹ |
| Chg in FII Hold | 1.15 % | Chg in DII Hold | -0.81 % | PAT Qtr | 426 Cr. | PAT Prev Qtr | 193 Cr. |
| RSI | 70.3 | MACD | 71.2 | Volume | 9,38,136 | Avg Vol 1Wk | 7,18,504 |
| Low price | 1,355 ₹ | High price | 2,474 ₹ | PEG Ratio | 23.1 | Debt to equity | 0.02 |
| 52w Index | 96.2 % | Qtr Profit Var | 3.00 % | EPS | 0.74 ₹ | Industry PE | 30.9 |
📊 GLENMARK shows a strong intraday setup with bullish momentum. RSI at 70.3 indicates overbought conditions, while MACD is highly positive (71.2), confirming strong upward momentum. Current price is well above DMA 50 and DMA 200, reflecting a strong trend. Volume is higher than the weekly average, supporting active intraday participation.
- 💰 Optimal Buy Price: 2,410–2,420 ₹ (near support zone)
- 📈 Profit-Taking Levels: 2,460 ₹ (first resistance), 2,474 ₹ (recent high)
- ⚠️ Stop-Loss: 2,390 ₹ (below intraday support)
- ⏳ If Already Holding: Exit near 2,460–2,474 ₹ if RSI crosses 72 or momentum indicators show exhaustion intraday.
Positive
✅ Strong price momentum with RSI and MACD bullish.
✅ PAT growth (426 Cr vs 193 Cr) shows earnings improvement.
✅ FII holdings increased (+1.15%), reflecting foreign investor confidence.
✅ Price well above DMA 50 and DMA 200, confirming trend strength.
✅ Market cap of 68,635 Cr indicates strong positioning in pharma sector.
Limitation
⚠️ High P/E (46.3) compared to industry average (30.9) suggests overvaluation.
⚠️ ROCE (9.72%) and ROE (7.35%) are relatively weak.
⚠️ PEG ratio of 23.1 indicates expensive valuation relative to growth.
⚠️ DII holdings decreased (-0.81%), showing reduced domestic institutional support.
⚠️ EPS of 0.74 ₹ is low compared to peers.
Company Negative News
🚫 No major negative news reported, though valuation concerns and weak return ratios persist.
Company Positive News
📢 Strong quarterly profit growth and increased FII holdings highlight investor confidence.
📢 Technicals show